Handelsbanken Fonder AB Grows Stake in Natera, Inc. $NTRA

by · The Markets Daily

Handelsbanken Fonder AB lifted its holdings in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 22.3% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 174,500 shares of the medical research company’s stock after acquiring an additional 31,800 shares during the period. Handelsbanken Fonder AB owned 0.13% of Natera worth $29,480,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in NTRA. Bank of Jackson Hole Trust purchased a new position in Natera in the first quarter valued at approximately $29,000. TCTC Holdings LLC grew its position in shares of Natera by 114.8% in the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock valued at $33,000 after buying an additional 124 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its position in shares of Natera by 83.5% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock valued at $33,000 after buying an additional 106 shares during the last quarter. Hilltop National Bank acquired a new stake in Natera during the 2nd quarter worth $33,000. Finally, Oliver Lagore Vanvalin Investment Group purchased a new stake in Natera in the second quarter valued at $36,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Stock Up 2.3%

Shares of NTRA stock opened at $230.63 on Friday. The stock’s 50-day moving average price is $186.27 and its 200 day moving average price is $167.81. The stock has a market capitalization of $31.83 billion, a PE ratio of -100.71 and a beta of 1.75. Natera, Inc. has a 52-week low of $125.38 and a 52-week high of $235.89.

Natera (NASDAQ:NTRA – Get Free Report) last announced its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The company had revenue of $592.18 million during the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The company’s revenue for the quarter was up 34.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.26) earnings per share. Analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NTRA has been the subject of several research analyst reports. Piper Sandler upped their price objective on shares of Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. BNP Paribas Exane raised Natera from an “underperform” rating to a “neutral” rating and set a $172.00 target price for the company in a research report on Monday, October 27th. Stephens raised their price target on Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Barclays lifted their price target on Natera from $210.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Finally, BTIG Research increased their price objective on Natera from $210.00 to $230.00 and gave the company a “buy” rating in a report on Friday, November 7th. Fifteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $220.29.

Check Out Our Latest Stock Report on Natera

Insider Activity at Natera

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the business’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $159.99, for a total value of $479,970.00. Following the transaction, the insider directly owned 117,559 shares of the company’s stock, valued at approximately $18,808,264.41. The trade was a 2.49% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Steven Leonard Chapman sold 160,703 shares of the company’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $199.96, for a total transaction of $32,134,171.88. Following the transaction, the chief executive officer owned 144,816 shares of the company’s stock, valued at approximately $28,957,407.36. The trade was a 52.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 236,116 shares of company stock worth $45,800,290 in the last three months. Insiders own 5.63% of the company’s stock.

Natera Company Profile

(Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Read More